biomarker-trends-header.png

CDx Partnership Bears Fruit with New FDA-Approved Test

This is an interesting example.

Predictive Biosciences Has Closed Due To Validation Requirement (Burrill Report article)

by John Audette | May 30, 2013 | Marketing, Test Developers, News

After raising over $30 million, and securing key channel access, Predictive Biosciences (developer of an LDT for bladder cancer) has closed operations because it couldn't afford the level of validation required by a payer.

Assay patenting instead of gene patenting to support diagnostic test development

Interesting point regarding alternative to gene patenting for diagnostics: assay patenting instead.

Barrier to Adoption: Uncertainty About Sample Requirements

Interesting survey (sponsored by Boehringer Ingelheim) of pulmonologists and pathologists regarding barriers to adoption of biomarker testing of lung cancer patients.

   

December

Webinar: 

Pharmacovigilance and Safety Biomarkers

RECORDING
New Call-to-action
FREE REPORT

Subscribe for Updates

Download our Free IVD Trends Report